Sontag Advisory LLC acquired a new position in shares of AbbVie Inc (NYSE:ABBV) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 4,036 shares of the company’s stock, valued at approximately $293,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Vivaldi Capital Management LLC acquired a new position in shares of AbbVie during the 4th quarter worth about $667,000. Kinneret Advisory LLC acquired a new position in AbbVie in the 4th quarter valued at about $1,903,000. Captrust Financial Advisors grew its stake in AbbVie by 1.4% in the 4th quarter. Captrust Financial Advisors now owns 102,960 shares of the company’s stock valued at $9,492,000 after buying an additional 1,433 shares during the last quarter. Geode Capital Management LLC grew its stake in AbbVie by 5.3% in the 4th quarter. Geode Capital Management LLC now owns 17,582,527 shares of the company’s stock valued at $1,617,957,000 after buying an additional 880,288 shares during the last quarter. Finally, Thoroughbred Financial Services LLC acquired a new position in AbbVie in the 4th quarter valued at about $1,150,000. Institutional investors and hedge funds own 68.21% of the company’s stock.

ABBV has been the topic of a number of research reports. Citigroup reiterated a “hold” rating on shares of AbbVie in a research note on Wednesday, June 26th. UBS Group raised shares of AbbVie from a “neutral” rating to a “buy” rating and cut their price objective for the company from $85.00 to $79.00 in a report on Thursday. Svb Leerink raised shares of AbbVie from a “market perform” rating to an “outperform” rating and set a $88.00 price objective for the company in a report on Wednesday, June 26th. TheStreet downgraded shares of AbbVie from a “b-” rating to a “c” rating in a report on Monday, August 26th. Finally, Leerink Swann raised shares of AbbVie to a “buy” rating in a report on Tuesday, July 2nd. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $91.20.

In related news, SVP Nicholas Donoghoe acquired 7,525 shares of the stock in a transaction that occurred on Thursday, August 29th. The stock was acquired at an average cost of $66.19 per share, for a total transaction of $498,079.75. Following the transaction, the senior vice president now directly owns 13,090 shares in the company, valued at $866,427.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jeffrey Ryan Stewart acquired 15,552 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were bought at an average price of $64.44 per share, with a total value of $1,002,170.88. Following the completion of the transaction, the senior vice president now owns 65,304 shares in the company, valued at $4,208,189.76. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 159,977 shares of company stock valued at $10,626,621. 0.08% of the stock is owned by corporate insiders.

Shares of AbbVie stock traded up $1.34 on Thursday, reaching $70.83. 8,489,181 shares of the stock were exchanged, compared to its average volume of 8,015,121. The firm’s 50 day moving average is $66.13 and its 200-day moving average is $74.81. AbbVie Inc has a one year low of $62.66 and a one year high of $96.60. The firm has a market cap of $98.61 billion, a PE ratio of 8.95, a P/E/G ratio of 1.58 and a beta of 0.95.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 26th. The company reported $2.26 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.21 by $0.05. The business had revenue of $8.26 billion during the quarter, compared to analysts’ expectations of $8.09 billion. AbbVie had a net margin of 12.62% and a negative return on equity of 182.70%. The firm’s quarterly revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.00 EPS. As a group, research analysts predict that AbbVie Inc will post 8.9 earnings per share for the current fiscal year.

The business also recently disclosed a — dividend, which will be paid on Friday, November 15th. Investors of record on Tuesday, October 15th will be given a dividend of $1.07 per share. This represents a yield of 6.4%. The ex-dividend date of this dividend is Friday, October 11th. AbbVie’s dividend payout ratio is 54.11%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Read More: How to Calculate Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.